{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T14:18:10Z","timestamp":1790432290071,"version":"4.1.0"},"reference-count":28,"publisher":"The Pediatric Pharmacy Association","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017]]},"abstract":"<jats:p>\n          <jats:bold>OBJECTIVES<\/jats:bold> The primary aim was to compare attainment of goal serum amikacin concentrations using two dosage regimens in patients admitted to a neonatal intensive care unit. Secondary objectives included comparison of percentages of supratherapeutic trough concentrations, and subtherapeutic and supratherapeutic peak concentrations.<\/jats:p>\n        <jats:p>\n          <jats:bold>METHODS<\/jats:bold> This was an Institutional Review Board\u2013approved, retrospective study of neonates receiving amikacin during January\u2013December 2013 (group 1) and January\u2013December 2014 (group 2). Group 1 received amikacin dosage consistent with published recommendations, whereas group 2 was dosed using a modified protocol that was based on postmenstrual and postnatal age. Goal serum amikacin peak concentration was defined as 20 to 35 mg\/L; hence, subtherapeutic and supratherapeutic peak concentrations were defined as &lt;20 mg\/L and &gt;35 mg\/L, respectively. Supratherapeutic trough concentrations were &gt;8 mg\/L. Between-group analysis was performed using Wilcoxon-Mann-Whitney test, Student <jats:italic>t<\/jats:italic>-test or \u03c7<jats:sup>2<\/jats:sup>, or Fisher exact analysis as appropriate with a p value &lt;0.05.<\/jats:p>\n        <jats:p>\n          <jats:bold>RESULTS<\/jats:bold> A total of 278 neonates were included (group 1: n = 144; group 2: n = 134). Most patients were male (60%) and were admitted for prematurity or respiratory distress (77%). The median gestational age in group 1 was 34.4 weeks (range, 30.0\u201337.9 weeks) versus group 2 at 36.9 weeks (range, 31.4\u201338.9 weeks), whereas the postnatal age was similar between both groups at 4 days. There was a significant increase in attaining goal peak amikacin concentrations between groups 1 and 2, 34% versus 84%, p &lt; 0.001, and decrease in supratherapeutic peak concentrations, 65% versus 12%, p &lt; 0.001. There was no significant difference in subtherapeutic peak or supratherapeutic trough concentrations.<\/jats:p>\n        <jats:p>\n          <jats:bold>CONCLUSIONS<\/jats:bold> A modified neonatal amikacin dosage protocol resulted in increased peak amikacin serum concentration compared with published dosage recommendations. Future research should focus on determination of the optimal dosage regimen in neonates.<\/jats:p>","DOI":"10.5863\/1551-6776-22.1.33","type":"journal-article","created":{"date-parts":[[2017,3,6]],"date-time":"2017-03-06T18:52:31Z","timestamp":1488826351000},"page":"33-40","source":"Crossref","is-referenced-by-count":7,"title":["Comparison of Amikacin Pharmacokinetics in Neonates Following Implementation of a New Dosage Protocol"],"prefix":"10.5863","volume":"22","author":[{"given":"Kaitlin M.","family":"Hughes","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter N.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael P.","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris C.","family":"Sekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert C.","family":"Welliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie L.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"key":"i1551-6776-22-1-33-b1","series-title":"Amikacin [package insert]","year":"2007","unstructured":"Amikacin [package insert]. Bedford, OH: Bedford Laboratories; 2007."},{"issue":"2","key":"i1551-6776-22-1-33-b2","series-title":"Antimicrob Agents Chemother","first-page":"265","article-title":"Amikacin pharmacokinetics and suggested dosage modifications for the preterm infant","volume":"34","year":"1990","unstructured":"Kenyon\n              CF\n            , KnoppertDC, LeeSK, \n          et al. Amikacin pharmacokinetics and suggested dosage modifications for the preterm infant. Antimicrob Agents Chemother. 1990;34(2):265\u2013268."},{"issue":"5","key":"i1551-6776-22-1-33-b3","series-title":"Antimicrob Agents Chemother","first-page":"1381","article-title":"Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children","volume":"46","year":"2002","unstructured":"Treluyer\n              JM\n            , MerleY, TonnelierS, \n          et al. Nonparametric population pharmacokinetic analysis of amikacin in neonates, infants, and children. Antimicrob Agents Chemother. 2002;46(5):1381\u20131387."},{"issue":"5","key":"i1551-6776-22-1-33-b4","series-title":"Pediatrics","first-page":"1006","article-title":"Management of neonates with suspected or proven early-onset bacterial sepsis","volume":"129","year":"2012","unstructured":"Polin\n              RA.\n            \n          \n          Management of neonates with suspected or proven early-onset bacterial sepsis. Pediatrics. 2012;129(5):1006\u20131015."},{"issue":"5","key":"i1551-6776-22-1-33-b5","series-title":"Pediatrics","first-page":"817","article-title":"Early onset neonatal sepsis: the burden of group B streptococcal and E. coli disease continues","volume":"127","year":"2011","unstructured":"Stoll\n              BJ\n            , HansenNI, SanchezPJ, \n          et al. Early onset neonatal sepsis: the burden of group B streptococcal and E. coli disease continues. Pediatrics. 2011;127(5):817\u2013826."},{"issue":"6","key":"i1551-6776-22-1-33-b6","series-title":"Acta Paediatr","first-page":"686","article-title":"Neonatal Escherichia coli infections: concerns regarding resistance to current therapy","volume":"89","year":"2000","unstructured":"Friedman\n              S\n            , ShahV, OhlssonA, MatlowAG.\n          Neonatal Escherichia coli infections: concerns regarding resistance to current therapy. Acta Paediatr. 2000;89(6):686\u2013689."},{"issue":"4","key":"i1551-6776-22-1-33-b7","series-title":"Pediatr Infect Dis J","first-page":"295","article-title":"Neonatal early onset Escherichia coli sepsis: trends in incidence and antimicrobial resistance in the era of intrapartum antimicrobial prophylaxis","volume":"23","year":"2004","unstructured":"Alarcon\n              A\n            , PenaP, SalasS, \n          et al. Neonatal early onset Escherichia coli sepsis: trends in incidence and antimicrobial resistance in the era of intrapartum antimicrobial prophylaxis. Pediatr Infect Dis J. 2004;23(4):295\u2013299."},{"key":"i1551-6776-22-1-33-b8","series-title":"Pediatric and Neonatal Dosing Handbook","year":"2016","unstructured":"Taketomo\n              CK\n            , HoddingJH, KrausDM, \n          eds. Pediatric and Neonatal Dosing Handbook. 22nd ed.Hudson, OH: Lexi-Comp Inc; 2016."},{"key":"i1551-6776-22-1-33-b9","series-title":"Micromedex Online, DrugPoint Summary","article-title":"Amikacin","year":"2014","unstructured":"Amikacin. Micromedex Online, DrugPoint Summary. Greenwood Village, CO: Truven Health Analytics Inc; 2014."},{"key":"i1551-6776-22-1-33-b10","series-title":"Micromedex Online, NeoFax and Pediatrics","article-title":"Amikacin","year":"2014","unstructured":"Amikacin. Micromedex Online, NeoFax and Pediatrics. Greenwood Village, CO: Truven Health Analytics Inc; 2014."},{"issue":"2","key":"i1551-6776-22-1-33-b11","series-title":"Am J Perinatol","first-page":"141","article-title":"Efficacy and renal toxicity of one daily dose of amikacin versus conventional dosage regime","volume":"24","year":"2007","unstructured":"Guadalupe Vasquez-Mendoza\n              G\n            , Vargas-OrigelA, Del Carmen Ramos-JimenezA, \n          et al. Efficacy and renal toxicity of one daily dose of amikacin versus conventional dosage regime. Am J Perinatol. 2007;24(2):141\u2013146."},{"issue":"1","key":"i1551-6776-22-1-33-b12","series-title":"J Clin Pharm Ther","first-page":"45","article-title":"The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis","volume":"36","year":"2011","unstructured":"Abdel-Hady\n              E\n            , El HamamsyM, HedayaM, \n          et al. The efficacy and toxicity of two dosing-regimens of amikacin in neonates with sepsis. J Clin Pharm Ther. 2011;36(1):45\u201352."},{"key":"i1551-6776-22-1-33-b13","series-title":"Arch Dis Child Fetal Neonatal Ed","first-page":"F294","article-title":"Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis","volume":"90","year":"2005","unstructured":"Nestaas\n              E\n            , BangstadHJ, SandvikL, \n          et al. Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2005;90:F294\u2013F300."},{"issue":"4","key":"i1551-6776-22-1-33-b14","series-title":"J Perinatol","first-page":"268","article-title":"Comparison of once-daily versus twice-daily gentamicin dosing regimens in infants > or = 2500 g","volume":"22","year":"2002","unstructured":"Agarwal\n              G\n            , RastogiA, PyatiS, \n          et al. Comparison of once-daily versus twice-daily gentamicin dosing regimens in infants > or = 2500 g. J Perinatol. 2002;22(4):268\u2013274."},{"issue":"3\u20134","key":"i1551-6776-22-1-33-b15","series-title":"Dev Pharmacol Ther","first-page":"220","article-title":"Once-a-day administration of amikacin in neonates: assessment of nephrotoxicity and ototoxicity","volume":"20","year":"1993","unstructured":"Langhendries\n              JP\n            , BattistiO, BertrandJM, \n          et al. Once-a-day administration of amikacin in neonates: assessment of nephrotoxicity and ototoxicity. Dev Pharmacol Ther. 1993;20(3\u20134):220\u2013230."},{"key":"i1551-6776-22-1-33-b16","series-title":"Otol Neurotol","first-page":"559","article-title":"Permanent gentamicin vestibulotoxicity","volume":"25","year":"2004","unstructured":"Black\n              FO\n            , PesxneckerS, StallingsV.\n          Permanent gentamicin vestibulotoxicity. Otol Neurotol. 2004;25:559\u2013569."},{"issue":"4","key":"i1551-6776-22-1-33-b17","series-title":"Pediatr Nephrol","first-page":"1453","article-title":"Etiology and outcome of acute kidney injury in children","volume":"25","year":"2010","unstructured":"Duzova\n              A\n            , BakkalogluA, KalyoncuM, \n          et al. Etiology and outcome of acute kidney injury in children. Pediatr Nephrol. 2010;25(4):1453\u20131461."},{"issue":"4","key":"i1551-6776-22-1-33-b18","series-title":"Drug Metab Lett","first-page":"286","article-title":"Covariates of amikacin clearance in neonates: the impact of postnatal age on predictability","volume":"2","year":"2008","unstructured":"Allegaert\n              K\n            , ScheersI, CosseyV, \n          et al. Covariates of amikacin clearance in neonates: the impact of postnatal age on predictability. Drug Metab Lett. 2008;2(4):286\u2013289."},{"issue":"15","key":"i1551-6776-22-1-33-b19","series-title":"Am J Health Syst Pharm","first-page":"1311","article-title":"Outcomes of a new dosage regimen of amikacin based on pharmacokinetic parameters of Korean neonates","volume":"71","year":"2014","unstructured":"An\n              SH\n            , KimJY, GwakHS.\n          Outcomes of a new dosage regimen of amikacin based on pharmacokinetic parameters of Korean neonates. Am J Health Syst Pharm. 2014;71(15):1311\u20131317."},{"issue":"3\u20134","key":"i1551-6776-22-1-33-b20","series-title":"Dev Pharmacol Ther","first-page":"167","article-title":"Pharmacokinetics of amikacin in neonates","volume":"20","year":"1993","unstructured":"Padovani\n              EM\n            , PistolesiC, FanosV, \n          et al. Pharmacokinetics of amikacin in neonates. Dev Pharmacol Ther. 1993;20(3\u20134):167\u2013173."},{"issue":"1","key":"i1551-6776-22-1-33-b21","series-title":"Clin Pharmacol Ther","first-page":"59","article-title":"Kinetics and dose calculations of amikacin in the newborn","volume":"20","year":"1976","unstructured":"Sardemann\n              H\n            , ColdingH, HendelJ, \n          et al. Kinetics and dose calculations of amikacin in the newborn. Clin Pharmacol Ther. 1976;20(1):59\u201366."},{"issue":"10","key":"i1551-6776-22-1-33-b22","series-title":"Pediatr Res","first-page":"810","article-title":"Influence of intrauterine maturation on the pharmacokinetics of amikacin in the neonatal period","volume":"16","year":"1982","unstructured":"Assael\n              BM\n            , PariniR, RusconiF, \n          et al. Influence of intrauterine maturation on the pharmacokinetics of amikacin in the neonatal period. Pediatr Res. 1982;16(10):810\u2013815."},{"issue":"6","key":"i1551-6776-22-1-33-b23","series-title":"Pediatr Cardiol","first-page":"761","article-title":"Gentamicin dosing for pediatric patients with congenital heart disease","volume":"31","year":"2010","unstructured":"Moffett\n              BS\n            , BorkSJ, MottAR.\n          Gentamicin dosing for pediatric patients with congenital heart disease. Pediatr Cardiol. 2010;31(6):761\u2013765."},{"issue":"9","key":"i1551-6776-22-1-33-b24","series-title":"Ann Pharmacother","first-page":"1193","article-title":"Use of a 4-mg\/kg\/24-hour empiric aminoglycoside dosing in preoperative neonates with congenital heart disease","volume":"46","year":"2012","unstructured":"Moffett\n              BS\n            , RossanoJW.\n          Use of a 4-mg\/kg\/24-hour empiric aminoglycoside dosing in preoperative neonates with congenital heart disease. Ann Pharmacother. 2012;46(9):1193\u20131197."},{"key":"i1551-6776-22-1-33-b25","series-title":"Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring","first-page":"285","article-title":"Aminoglycosides","year":"2006","unstructured":"Schentag\n              JJ\n            , MeagherAK, JefilleRW.\n          Aminoglycosides. InBurtonME, ShawLM, SchentagJJ, EvansWE, eds. Applied Pharmacokinetics and Pharmacodynamics: Principles of Therapeutic Drug Monitoring. 4th ed.Baltimore, MD: Lippincott Williams and Wilkins; 2006:285\u2013327."},{"key":"i1551-6776-22-1-33-b26","article-title":"Second Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines 2008. Gentamicin--ototoxicity in children","unstructured":"World Health Organization. \n          Second Meeting of the Subcommittee of the Expert Committee on the Selection and Use of Essential Medicines 2008. Gentamicin--ototoxicity in children. http:\/\/www.who.int\/selection_medicines\/committees\/subcommittee\/2\/gentamicin_rev.pdf. Accessed August 1, 2014."},{"issue":"9","key":"i1551-6776-22-1-33-b27","series-title":"Am J Perinatol","first-page":"745","article-title":"Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants","volume":"30","year":"2013","unstructured":"Sivanandan\n              S\n            , BaliV, SoraishanAS, \n          et al. Effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus in preterm infants. Am J Perinatol. 2013;30(9):745\u2013750."},{"issue":"3","key":"i1551-6776-22-1-33-b28","series-title":"J Perinatol","first-page":"226","article-title":"A gestation- and postnatal age-based reference chart for assessing renal function in extremely premature infants","volume":"28","year":"2008","unstructured":"Thayyil\n              S\n            , SheikS, KempleyST, \n          et al. A gestation- and postnatal age-based reference chart for assessing renal function in extremely premature infants. J Perinatol. 2008;28(3):226\u2013229."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/22\/1\/article-p33.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/meridian.allenpress.com\/jppt\/article-pdf\/22\/1\/33\/1787953\/1551-6776-22_1_33.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/22\/1\/article-p33.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/22\/1\/article-p33.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,16]],"date-time":"2025-05-16T00:47:44Z","timestamp":1747356464000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/22\/1\/article-p33.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":28,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-22.1.33","relation":{},"ISSN":["1551-6776"],"issn-type":[{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}